DE60237145D1 - quinazoline derivatives - Google Patents
quinazoline derivativesInfo
- Publication number
- DE60237145D1 DE60237145D1 DE60237145T DE60237145T DE60237145D1 DE 60237145 D1 DE60237145 D1 DE 60237145D1 DE 60237145 T DE60237145 T DE 60237145T DE 60237145 T DE60237145 T DE 60237145T DE 60237145 D1 DE60237145 D1 DE 60237145D1
- Authority
- DE
- Germany
- Prior art keywords
- quinazoline derivatives
- agent
- compound
- theprophylaxis
- racemate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
A compound of the formula (I) <CHEM> or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for theprophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001045827 | 2001-02-21 | ||
JP2001353525 | 2001-11-19 | ||
PCT/JP2002/001575 WO2002066445A1 (en) | 2001-02-21 | 2002-02-21 | Quinazoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60237145D1 true DE60237145D1 (en) | 2010-09-09 |
Family
ID=26609852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60237145T Expired - Lifetime DE60237145D1 (en) | 2001-02-21 | 2002-02-21 | quinazoline derivatives |
Country Status (10)
Country | Link |
---|---|
US (2) | US7294629B2 (en) |
EP (1) | EP1369418B1 (en) |
JP (1) | JP4285996B2 (en) |
KR (1) | KR100861486B1 (en) |
CN (1) | CN1264824C (en) |
AT (1) | ATE475652T1 (en) |
CA (1) | CA2442742A1 (en) |
DE (1) | DE60237145D1 (en) |
TW (1) | TWI309647B (en) |
WO (1) | WO2002066445A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
WO2005026150A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
CN1882570B (en) * | 2003-09-19 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | Quinazoline derivatives |
ES2279441T3 (en) | 2003-09-19 | 2007-08-16 | Astrazeneca Ab | DERIVATIVES OF QUINAZOLINA. |
BRPI0414735A (en) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | quinazoline derivative, compound, pharmaceutical composition, use of quinazoline derivative, method for producing an antiproliferative effect on a warm-blooded animal, and process for the preparation of a quinazoline derivative |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
US7767670B2 (en) * | 2003-11-13 | 2010-08-03 | Ambit Biosciences Corporation | Substituted 3-carboxamido isoxazoles as kinase modulators |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
US20070270589A1 (en) * | 2003-11-28 | 2007-11-22 | Mitsubishi Pharma Corporation | Quinazoline Derivative and Process for Producing the Same |
JP5032851B2 (en) | 2004-02-03 | 2012-09-26 | アストラゼネカ アクチボラグ | Quinazoline derivatives |
GEP20084551B (en) | 2004-05-06 | 2008-11-25 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
US20080200433A1 (en) * | 2004-09-01 | 2008-08-21 | Tsuyoshi Suzuki | Molecular Chaperone Function Regulator |
ATE501148T1 (en) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTI-TUMOR AGENTS |
EP1854789B1 (en) | 2005-02-23 | 2013-10-09 | Shionogi & Co., Ltd. | Quinazoline derivative having tyrosine kinase inhibitory activity |
TW200640904A (en) * | 2005-02-26 | 2006-12-01 | Astrazeneca Ab | Quinazoline derivatives |
JP4993205B2 (en) * | 2005-03-30 | 2012-08-08 | 塩野義製薬株式会社 | Pyrimidine derivatives having tyrosine kinase inhibitory action |
ATE488513T1 (en) | 2005-09-20 | 2010-12-15 | Astrazeneca Ab | 4-(1H-INDAZOLE-5-YLAMINO)QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER |
JP2009529045A (en) * | 2006-03-03 | 2009-08-13 | アベオ ファーマシューティカルズ, インコーポレイテッド | Process for synthesizing 7-alkynyl-4-aminoquinazolines and related intermediates |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
WO2008095847A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
WO2009098061A1 (en) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
AU2009247782C1 (en) | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
JP5539351B2 (en) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them |
BR112012022868A2 (en) * | 2010-03-16 | 2018-06-05 | Merck Patent Gmbh | morpholinylquinazolines |
KR102061743B1 (en) * | 2011-03-04 | 2020-01-03 | 뉴젠 세러퓨틱스 인코포레이티드 | Alkyne substituted quinazoline compound and methods of use |
CN102918029B (en) | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof |
EP2802568A1 (en) | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
CN103254143B (en) * | 2013-04-26 | 2015-10-07 | 浙江工业大学 | 4-[4-(2-diethylin kharophen) anilino]-6-substituted quinazoline compounds and Synthesis and applications |
WO2014177038A1 (en) | 2013-04-28 | 2014-11-06 | Sunshine Lake Pharma Co., Ltd. | Aminoquinazoline derivatives and their salts and methods of use thereof |
JP6564771B2 (en) | 2013-07-11 | 2019-08-21 | エイシア バイオサイエンシーズ インコーポレイテッド | Pyrimidine derivatives as kinase inhibitors |
CN107949388B (en) | 2015-10-09 | 2021-10-26 | 艾森医药公司 | Pharmaceutical salts, physical forms and compositions of pyrrolopyrimidine kinase inhibitors and methods of making the same |
US10953016B2 (en) * | 2017-01-30 | 2021-03-23 | Shionogi & Co., Ltd. | Solid dosage form containing quinazoline derivative |
CN111212837A (en) | 2017-04-07 | 2020-05-29 | 艾森医药公司 | Pharmaceutical salts, physical forms and compositions of pyrrolopyrimidine kinase inhibitors and methods of making the same |
CN110577514B (en) * | 2018-06-08 | 2022-07-05 | 江苏威凯尔医药科技有限公司 | Human epidermal growth factor receptor inhibitor and preparation method and application thereof |
WO2019233459A1 (en) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Human epidermal growth factor receptor inhibitor, preparation method therefor and use thereof |
EP4013749A1 (en) * | 2019-08-15 | 2022-06-22 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3134236B2 (en) | 1992-01-30 | 2001-02-13 | 株式会社林原生物化学研究所 | Method for producing high α-glycosyl-L-ascorbic acid content and separation system for the production |
JP2994165B2 (en) | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | Quinazoline derivative, method for producing the same, and pharmaceutical preparation containing the quinazoline derivative for obtaining anticancer activity |
DE69710712T3 (en) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | REVERSIBLE INHIBITORS OF TYROSINE KINASEN |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
US6251912B1 (en) * | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
DZ3407A1 (en) * | 2000-06-22 | 2001-12-27 | Pfizer Prod Inc | |
US20070270589A1 (en) * | 2003-11-28 | 2007-11-22 | Mitsubishi Pharma Corporation | Quinazoline Derivative and Process for Producing the Same |
-
2002
- 2002-02-21 JP JP2002565961A patent/JP4285996B2/en not_active Expired - Fee Related
- 2002-02-21 DE DE60237145T patent/DE60237145D1/en not_active Expired - Lifetime
- 2002-02-21 TW TW091102988A patent/TWI309647B/zh active
- 2002-02-21 WO PCT/JP2002/001575 patent/WO2002066445A1/en active Application Filing
- 2002-02-21 CN CNB028052609A patent/CN1264824C/en not_active Expired - Fee Related
- 2002-02-21 US US10/468,788 patent/US7294629B2/en not_active Expired - Fee Related
- 2002-02-21 AT AT02700688T patent/ATE475652T1/en not_active IP Right Cessation
- 2002-02-21 CA CA002442742A patent/CA2442742A1/en not_active Abandoned
- 2002-02-21 KR KR1020037011020A patent/KR100861486B1/en not_active IP Right Cessation
- 2002-02-21 EP EP02700688A patent/EP1369418B1/en not_active Expired - Lifetime
-
2007
- 2007-06-28 US US11/819,679 patent/US20070265260A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1492860A (en) | 2004-04-28 |
US20070265260A1 (en) | 2007-11-15 |
ATE475652T1 (en) | 2010-08-15 |
JP4285996B2 (en) | 2009-06-24 |
JPWO2002066445A1 (en) | 2004-06-17 |
WO2002066445A1 (en) | 2002-08-29 |
EP1369418A4 (en) | 2005-09-14 |
US7294629B2 (en) | 2007-11-13 |
EP1369418A1 (en) | 2003-12-10 |
TWI309647B (en) | 2009-05-11 |
US20040116422A1 (en) | 2004-06-17 |
CN1264824C (en) | 2006-07-19 |
EP1369418B1 (en) | 2010-07-28 |
KR100861486B1 (en) | 2008-10-02 |
KR20030086269A (en) | 2003-11-07 |
CA2442742A1 (en) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE475652T1 (en) | QUINAZOLINE DERIVATIVES | |
ATE307810T1 (en) | IMIDAZOLE-2-CARBONIC ACID AMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | |
EA200501849A1 (en) | DERIVATIVES OF PYRAZOLOHINAZOLINE: METHOD FOR OBTAINING AND USING AS KINAZ INHIBITORS | |
HRP20090281T1 (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
BRPI0209216B8 (en) | quinoline and quinazoline derivatives, pharmaceutical compositions comprising the same and their uses | |
DE69528005D1 (en) | Prolineamid derivatives | |
EA200500508A1 (en) | DIARYL ETHERS AS AN ANTAGONIST OPIOID RECEPTOR | |
WO2001019829A3 (en) | Pyrazolopyrimidines as therapeutic agents | |
ATE450533T1 (en) | CARBOXAMIDE DERIVATIVES | |
ATE371656T1 (en) | HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | |
NO20055655D0 (en) | Use of azetidinecarboxamide derivatives in therapy | |
NO20052698L (en) | 4 (phenylpiperazinylmethyl) benzamide derivatives and their use in the treatment of pain and gaseous tract disorders. | |
EA200801308A1 (en) | COMBINATIONS INCLUDING CDK INHIBITOR AND ANTIBODY GROWTH FACTOR OR ANTIMITOTIC | |
ATE327225T1 (en) | NEW USE OF BENZOTHIAZOLE DERIVATIVES | |
DK1465625T3 (en) | Dissolved topoisomerase poisons | |
SE0102440D0 (en) | New compound | |
ATE390923T1 (en) | TOPOISOMERASE TOXICANTS | |
ATE424200T1 (en) | SOLUBILIZED TOPOISOMERASE POISON AGENT | |
ATE326451T1 (en) | QUINAZOLINE DERIVATIVES AND THERAPEUTIC USES THEREOF | |
ATE287397T1 (en) | CHINOLINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | |
ATE293961T1 (en) | USE OF HYDANTOIN AND ITS DERIVATIVES AGAINST HYPALBUMINAEMIA | |
SE9900190D0 (en) | New compounds | |
TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
SE0301371D0 (en) | New Compounds | |
DE60211866D1 (en) | THIOPHEN SUBSTITUTED AMINE DERIVATIVES AS GLYT-1 INHIBITORS |